Simtuzumab, a monoclonal antibody targeting LOXL2, was tested in phase II trials for pancreatic cancer and idiopathic pulmonary fibrosis, but clinical efficacy has been limited (NCT01672853) [195, 196, 197]. Here, LOXL2 is linked to pulmonary fibrosis.